drugset / Trial / NCT01111851

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

NCT01111851

Phase 1 Completed 16 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.

Timeline

Start
2010-04
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 165 mg Oral
Subject Aprepitant Other / unclassified 250 mg Oral
Subject Fosaprepitant Other / unclassified 150 mg Intravenous
Subject MK0999 Unknown 5 ug Intravenous
Subject MK0999 Unknown 100 mbq Intravenous
Background Dexamethasone Small molecule 8 mg Oral
Background Ondansetron Other / unclassified 32 mg Intravenous